Registry of Lobbyists
Version 4 of 8 (1998-01-19 to 1998-08-11) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Organization: |
CANADIAN SOCIETY OF HOSPITAL PHARMACISTS (CSHP)
350 - 1145 HUNT CLUB ROAD OTTAWA, ON K1V 0Y3 Canada |
| Telephone number: | 613-736-9733 |
| Fax number: | 613-736-5660 |
| Responsible officer name and position during the period of this registration: | WILLIAM J LESLIE, EXECUTIVE DIRECTOR |
| Description of the organization's activities: | THE CANADIAN SOCIETY OF HOSPITAL PHARMACISTS (CSHP) IS THE NATIONAL VOLUNTARY ORGANIZATION OF PHARMACISTS WHO SHARE AN INTEREST IN PHARMACY PRACTICE IN HOSPITALS AND RELATED HEALTH CARE SETTINGS.CSHP'S VISION IS: COMMITTED CAREGIVERS.... CHALLENGING EACH OTHER THROUGH SHARING & EDUCATION , LEADING PHARMACY THROUGH STANDARDS & INNOVATION. THE RELATED VISION OBJECTIVES ARE:1- ENCOURAGE MEMBERS TO DEVELOP & SHARE INNOVATIVE DIRECT PATIENT CARE PRACTIVE MODELS & EXPERIENCE2- PROMOTE THE DIRECT PATIENT CARE ROLE OF THE PHARMACIST TO: MEMBERS, PATIENTS, EDUCATORS, STUDENTS, GOV'T, HEALTH CARE PROVIDERS & ORGANIZATIONS3- PROVIDE ACCESSIBLE EDUCATION TO ASSIST MEMBERS IN ACHIEVING A DIRECT PATIENT CARE ROLE |
| Organization's membership or classes of membership: | 1- ACTIVE MEMBERS ARE PHARMACISTS LICENSED OR REGISTERED WITH A PHARMACY REGULATORY BODY IN CANADA OR PERSONS WITH A PROFESSIONAL DEGREE IN PHARMACY2- HONORARY MEMBERS - ELECTED BY A 2/3 VOTE OF THE COUNCIL OF THE SOCIETY3- STUDENT MEMBERS ARE PERSONS ENROLLED IN A BACCALAUREATE DEGREE PROGRAM IN PHARMACY4- SUPPORTING MEMBERS ARE PERSONS NOT ELIGIBLE FOR OTHER MEMBERSHIP CATEGORIES5- CORPORATE MEMBERS ARE CORPORATIONS WHO SUPPORT THE OBJECTIVES OF AND PAY FEES TO THE SOCIETY |
| Was the organization funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Name: | WILLIAM LESLIE |
| Position title: | EXECUTIVE DIRECTOR |
| Public offices held: | N/A. Disclosure of this information was not a requirement prior to June 20, 2005. |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | DRUGS DIRECTORATE, HEALTH PROTECTION BRANCH, Environment Canada, Health Canada (HC), Industry Canada, Patented Medicine Prices Review Board (PMPRB) |
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Informal communications, Meetings, Telephone calls, Written communications, whether in hard copy or electronic format |
| Subject Matter: Areas of Concern: | Health |
| Subject Matter: Retrospective: | ONGOING JOINT INITIATIVE WITH TPD (THERAPEUTIC PRODUCTS DIR.) REGARDING ESTABLISHMENT LICENSES & HOSPITAL COMPOUNDING PRACTICES; DISCUSSIONS WITH TPD ON USP MEDICATION INCIDENT REPORTING AND POSSIBLE CANADIAN APPLICATONS; RESPONSES TO REQUESTS FOR INPUT: RX TO OTC SWITCH FOR NIZATIDINE 75 MGS., RX TO OTC SWITCH FOR NICOTINE PATCHES; SPECIAL ACCESS PROGRAMME; DRAFT GUIDELINES FOR INCLUSION OF PAEDIATRIC PATIENTS IN CLINICAL TRIALS; POLICY ON SUBMISSION REQUIREMENTS FOR TOPICAL NSAID'S; RX TO OTC SWITCH FOR SODIUM CROMOGLYCATE NASAL SOLUTION 2%; ESTABLISHMENT LICENSE FEE REGULATIONS; POLICY ON DEREGULATION OF PROHIBITED SUBSTANCES; "LOOK ALIKE SOUND ALIKE" ( LASA) DRUG NAMES; NARCOTIC & CONTROLLED DRUG INSPECTIONS; CLARIFY ISSUE OF DRUG RESEARCH LAB CLOSURES; ELECTRONIC HOSPITAL CHART & ELECTRONIC SIGNATURE FOR NARCOTIC & CONTROLLED DRUG ORDERS; BLOOD SYSTEM SYMPOSIUM; TPD COST RECOVERY III CONSULTATIONS; TPD PRODUCT LICENSING FRAMEWORK; ELIMINATION OF CFC'S FROM METERED DOSE INHALERS; F/P/T REPORT ON PHARMACEUTICAL COSTS & UTILIZATION; NATIONAL PHARMACARE PROGRAM CONSULTATIONS WORIKRESM 4 MG.; REGULATIONS FOR WOMEN IN CLINICAL TRIALS; REGULATIONS FOR HUMAN NEW DRUG SUBMISSION [ BIOTECHNOLOGY]; REGULATIONS FOR PRODUCT MONOGRAPHS; REGULATIONS FOR ESTABLISHMENT LICENSES; COMPARATIVE DRUG ADVERTISING CLAIMS; BIOEQUIVALENCE REQUIREMENTS; REGS FOR NEW CONTROLLED SUBSTANCES ACT; GUIDELINES FOR RADIOPHARMACEUTICAL Q.A.; REGS FOR COSMETIC PRODUCTS - LABEL & CLAIM ISSUES; SPECIAL ACCESS PROGRAM; REGS FOR SUPPLEMENTAL NEW DRUG SUBMISSIONS; RX TO OTC SWITCH FOR RANITIDINE 75 MG.; STANDARDS FOR COMPARATIVE BIOAVAILABILITY STUDIES; NOTICE OF COMPLIANCE WITH CONDITIONS POLICY; PRINCIPLES FOR DIRECT TO CONSUMER ADS; NUMEROUS MEETINGS RE: ESTABLISHMENT LICENSES & HOSPITAL COMPOUNDING PRACTICES (GMP & HOSPITAL PHARMACY); C-91 [ DRUG PATENTS]; PARTIPATION IN HEALTH CANADA'S WORKSHOPS ON ANTIBIOTIC RESISTANCE & ON CFC PROPELLANTS. |
| Subject Matter: Prospective: | CONTINUE TO WORK WITH TPD (THERAPEUTIC PRODUCTS DIR) ON POLICY AND HOSPITAL BASED DRUG COMPOUNDING; RESPOND TO RELEVANT HEALTH RELATED ITEMS PUBLISHED IN CANADA GAZETTE; RESPOND TO TPD REQUESTS FOR INPUT & PARTICIPATION IN WORKSHOPS; PARTICIPATE IN DISCUSSIONS ON NATIONAL PHARMACARE PROGRAM. |